Innate Pharma S.A.
IPHA
$1.93
-$0.04-2.03%
NASDAQ
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Net Income | -36.82M | -22.56M | -8.20M | -36.10M | -63.50M |
| Total Depreciation and Amortization | 2.80M | 4.17M | 5.50M | 5.94M | 6.35M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 401.50K | 1.30M | 2.17M | 24.07M | 45.66M |
| Change in Net Operating Assets | 14.07M | -10.33M | -34.70M | -28.18M | -21.57M |
| Cash from Operations | -19.55M | -27.43M | -35.22M | -34.27M | -33.06M |
| Capital Expenditure | -351.40K | -367.30K | -379.40K | -415.60K | -450.60K |
| Sale of Property, Plant, and Equipment | 162.30K | 162.30K | 162.30K | 81.60K | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 23.80M | 23.18M | 22.55M | 12.59M | 2.49M |
| Cash from Investing | 23.61M | 22.97M | 22.33M | 12.26M | 2.04M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -5.19M | -3.77M | -2.36M | -2.51M | -2.66M |
| Issuance of Common Stock | 140.00K | 267.50K | 395.00K | 374.50K | 354.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | 97.00K | 194.00K |
| Cash from Financing | -5.46M | -3.81M | -2.13M | -2.18M | -2.23M |
| Foreign Exchange rate Adjustments | -138.20K | 79.00K | 296.30K | 350.50K | 402.20K |
| Miscellaneous Cash Flow Adjustments | 0.00 | 0.00 | 0.00 | 1.50K | 3.00K |
| Net Change in Cash | -1.54M | -8.18M | -14.72M | -23.85M | -32.84M |